Pembrolizumab-Induced Eruptive Keratoacanthomas and Lichen Planus in a Lung Cancer Patient.

Reports of pembrolizumab-induced lichen planus and eruptive keratoacanthomas are limited in the literature. Here, we describe the unique concurrence of both lichen planus and eruptive keratoacanthomas in a patient who received pembrolizumab for non-small cell lung cancer (NSCLC). Although several therapies have been proposed, we show that pembrolizumab-induced lichen planus and keratoacanthomas can be controlled with the conservative management of topical corticosteroids and intralesional corticosteroids, respectively, allowing patients to continue pembrolizumab therapy.